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Background: Streptococcus pneumoniae infections, which place a considerable burden on healthcare resources, can
be reduced in a cost-effective manner using a 7-valent pneumococcal conjugate vaccine (PCV-7). We compare the
cost effectiveness of a 13-valent PCV (PCV-13) and a 10-valent pneumococcal non-typeable Haemophilus influenzae
protein D conjugate vaccine (PHiD-CV) with that of PCV-7 in Turkey.
Methods: A cost-utility analysis was conducted and a decision analytical model was used to estimate the
proportion of the Turkish population <10 years old that would experience 10 mutually exclusive outcomes over the
course of 1 year from a perspective of a healthcare system. Model outcomes were adjusted according to the
population demographics and region-specific serotype distribution in Turkey. Health outcomes and direct
healthcare costs were simulated for PCV-7, PCV-13 and PHiD-CV.
Results: PCV-13 and PHiD-CV are projected to have a substantial impact on pneumococcal disease in Turkey versus
PCV-7, with 2,223 and 3,156 quality-adjusted life years (QALYs) and 2,146 and 2,081 life years, respectively, being
saved under a 3+1 schedule. Projections of direct medical costs showed that a PHiD-CV vaccination programme
would provide the greatest cost savings, offering additional savings of US$11,718,813 versus PCV-7 and US
$8,235,010 versus PCV-13. Probabilistic sensitivity analysis showed that PHiD-CV dominated PCV-13 in terms of
QALYs gained and cost savings in 58.3% of simulations.
Conclusion: Under the modeled conditions, PHiD-CV would provide the most cost-effective intervention for
reducing pneumococcal disease in Turkish children.Background
Infection with Streptococcus pneumoniae can result in
invasive pneumococcal disease (IPD) (e.g. meningitis
and bacteremia) and non-invasive pneumococcal disease
(e.g. community-acquired pneumonia [CAP] and acute
otitis media [AOM]). In Turkey in 2000, lower respiratory
infections were the fifth most common cause of death in
the total population (accounting for 4% of deaths), and the
second most common cause of death among 0-14-year
olds (14% of deaths); and meningitis was the fifth most
common cause of death among 0-14-year olds (3% of
deaths) [1]. Results in terms of disability-adjusted life* Correspondence: mbakir@marmara.edu.tr
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reproduction in any medium, provided the oryears (DALYs) were similar [1], showing that these
infections are a serious cause of morbidity as well as
mortality.
Based on the high burden of pneumococcal diseases
(particularly in young children), increasing antibiotic
resistance, and the efficacy [2,3], safety [2] and cost-
effectiveness [4] of a 7-valent pneumococcal conjugate
vaccine (PCV-7; Pfizer), the World Health Organization
(WHO) recommended in 2007 that pneumococcal vac-
cination should be included in national childhood immu-
nization programs [5]. This was implemented in Turkey
in November 2008 [6]. Other vaccines recently licensed
in Turkey are a 13-valent pneumococcal conjugate
vaccine (PCV-13; Pfizer) and one that contains 10
pneumococcal serotypes and a carrier protein derived
from non-typeable Haemophilus influenzae (NTHi):
pneumococcal non-typeable H. influenzae protein Dd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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ter has the added advantage of providing protection
against AOM caused by NTHi [7], which causes around
a third of AOM cases (with another third being due
to S. pneumoniae [8]).
In 2003, the World Bank issued a report highlighting
the inadequacies of health services in Turkey, and the
poor health status of Turkish people compared to those
in other middle-income countries [9]. The main aims
outlined in the report were to improve access to health
services, quality of care and health outcomes; and in-
crease cost-effectiveness [9]. Since adopting the Health
Transformation Program, resource use in Turkey has
been optimized and the health system has become more
effective, efficient and equitable [6]. In 2009, the Turkish
budget for vaccination was 205 million Turkish Lira
(TL) [6]. By comparison, a budget of only 14 million
TL was allocated for vaccination in 2002 [6]. Further
improvement of Turkey’s vaccination program was one
of the priorities set out by a Biennial Collaborative
Agreement between the Ministry of Health of Republic
of Turkey and the Regional Office for Europe of the
WHO in 2010 [10]. The aims were to maintain polio-free
status, eliminate measles and rubella, provide equit-
able access to vaccines, and include new immunizationFigure 1 Model structure: decision tree framework. The 10 mutually ex
represented by the 10 branches of the decision analytical model. Although
sequelae, these were not included in the presented analysis, due to a lack
PCV-7 = 7-valent pneumococcal conjugate vaccine, PCV-13 = 13-valent pn
non-typeable Haemophilus influenzae Protein D conjugate vaccine.products and technologies for vaccine-preventable dis-
eases [10].
Immunization is generally considered to be one of the
most cost-effective health investments [11]. In Turkey,
children are routinely vaccinated against tuberculosis,
hepatitis B, diphtheria, pertussis, tetanus, H. influenzae
type b, polio, measles, mumps, rubella, and meningitis,
as well as receiving PCV-7 [6,12]. However, with the
introduction of the newer pneumococcal vaccines, the
relative cost-effectiveness of PCV-7, PCV-13 and PHiD-
CV needs to be ascertained. Therefore, the objective of
this paper is to estimate the public health and economic




The health economic model was used to conduct a cost-
utility analysis from the perspective of a healthcare sys-
tem. This model was derived from a population-based
model previously described by De Wals et al. [13]. The
model is comprised of a decision tree framework that
terminates in 10 mutually exclusive pneumococcal-related
health outcomes (Figure 1). For each vaccination program
considered, the proportion of the Turkish populationclusive health outcomes for pneumococcal-related disease are
the model is capable of estimating the disutility of long-term
of accurate, region-specific data. AOM = acute otitis media,
eumococcal conjugate vaccine, PHiD-CV = pneumococcal
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1-year period is estimated. Vaccination schedules are
assumed to exert a “steady state” effect on the entire
population. This implies that the given vaccination pro-
gram has been established long enough to have a con-
sistent effect year after year. This evaluation estimates
the direct impact of vaccination on children at risk aged
0–9 years only. Hence, we assumed that a steady state
will have been reached 10 years after vaccination of the
first birth cohort. In contrast to traditional lifetime
Markov models, our model evaluates cost effectiveness
in a single year (once equilibrium has been established).
Finally, the model is stratified by a series of age compart-
ments, which enables estimates to be adjusted according
to population demographics and age-specific parameters.
The model was used to compare three vaccination
scenarios: a currently existing PCV-7 vaccination pro-
gram compared with PHiD-CV or PCV-13; and direct
comparison of PHiD-CV versus PCV-13 given in a 3+1
schedule consisting of three doses in the first 6 months
of life, with a booster at 12–15 months of age. For the
three vaccination scenarios, all children were assumed to
receive the full course of doses with an overall coverage
rate of 84%. This estimation was based on data from the
US National Immunization Survey 5 years after PCV-7
was introduced [14].
Epidemiology data
The population of Turkey (estimated at 72 million) and
age-specific demographic data were obtained from na-
tional census data for the year 2000 adjusted to the
current population size [15]. This corresponded with a
total vaccinated population (defined as children aged
2–13 months) of 1,400,000 individuals. For children aged
<5 years of age, disease incidence of acute episodes and
rates of hospitalization and ambulatory cases for IPD and
CAP were taken from a previous study of admissions to
12 Istanbul hospitals, which cover 65% of the city’s
population [16], and a National Burden of Disease












<1 14.6 45 339
1-<2 10 25 132
2-<3 5 25 21
3-<4 5 12.5 21
4-<5 5 12.5 21
5-<10 1.2 0.5 15.5
AOM acute otitis media, GP general practitioner.turn represents 19% of the overall Turkey population
of 70 million people. We assumed that 1/3 of children
aged <5 years would experience AOM, as has been
reported in studies from other European countries
[18,19]. Data specific to Turkey were not available for
children aged 5–9 years. Therefore, the incidences of
acute IPD, CAP and AOM for these children were
based on the average incidences in children aged <5
years in Turkey and the ratio of incidences in children
aged <5 and 5–9 years in the UK. Data for IPD, CAP
and AOM in the UK were taken from the Health
Protection Agency [20], Hospital Episode Statistics
[21] and Melegaro and Edmunds [19], respectively.
Hospitalization rates for AOM and the proportion of
hospitalized AOM cases requiring myringotomy were
based on Ministry of Health statistics for the year 2004
[17]. Although AOM can result in various complica-
tions, these were not included in the current analysis.
The model assumes that 35.9% of AOM cases are at-
tributable to S. pneumoniae and that 32.3% of AOM
cases are attributable to NTHi. These estimates are cal-
culated from Leibovitz [8], which estimates the cause of
disease in children from 23 different datasets across mul-
tiple countries. The weighted average across all data sets
was calculated for S. pneumoniae and NTHi.
The previous study of IPD and CAP <5 years of
age in 12 Istanbul hospitals [16] was approved by the
Research Ethical Committee of Marmara University
School of Medicine. Permission for access to patient
charts data was provided by both Turkish Ministry of
Health and management of each hospital.
Quality of life
The model used two types of utility values: normative
utility values (the mean utility of living for 1 year for the
general population) and the disutilities associated with a
disease (the reduction in the normative utility in a patient
presenting with a certain condition). Due to the lack
of local data in Turkey, all utility values were obtained















Table 2 Normative utility values for the general
population (men and women)
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the normative utility allocated to each age, and Table 3
[22,23] shows the disutilities the model used for each
condition, measured as the amount of utility lost in a
year. For most patients, the quality of life reduction
associated with the acute episode is limited to a short
period of time (1–2 weeks for pneumonia, meningitis
or bacteremia; and 1–2 days for AOM). The disutility
values generated by these acute episodes are therefore
small (0.005-0.023) in annual terms.
In our analysis, we used only short-term disutility
values for otitis media, which do not take into account
pain and hearing loss associated with chronic or recur-
rent middle ear infection. Therefore, our study is conser-
vative with respect to PHiD-CV. Disutility values for
IPD, CAP and AOM were varied by ± 50% in a sensitivity
analysis.
Cost parameters
PHiD-CV, PCV-7 and PCV-13 were assumed to have
equal cost per dose (US$30) and per administration
(US$3.26). Disease-related costs were estimated from a
healthcare payer perspective, whereby only direct med-
ical costs incurred for medical treatment were consid-
ered. Costs incurred during treatment of a pediatric




Meningitis (inpatient)* 0.023 [22]
Bacteremia (inpatient)* 0.008 [22]
Pneumonia (inpatient)* 0.008 Assumed to be the same
as inpatient bacteremia
Pneumonia (outpatient)* 0.006 [22]
AOM (outpatient)* 0.005 [23]
AOM hospitalized
myringotomy*
0.005 Assumed to be the same
as for AOM outpatient
*Per episode.
AOM acute otitis media.pneumococcal bacteremia (US$500), were sourced from
a previous study in 12 hospitals in Istanbul [16]. Costs
incurred for cases of inpatient pneumonia (US$325)
and outpatient pneumonia (US$43), and cases of otitis
media requiring hospitalization (US$438) or primary
care physician visits (US$30), were sourced from a
Turkish National Burden of Disease Study [17].
Vaccine efficacy
The model considers individuals to be protected by
vaccination from 2 months to 10 years of age. Vaccine
efficacy is subdivided into three distinct periods: an
initial ramp-up phase that occurs over the course of
vaccine administration (2–13 months), a full efficacy
phase (13 months-3 years) and a waning efficacy phase
(3–10 years) (Figure 2).
Direct vaccine effectiveness was estimated using data
collected from prior clinical trials and post-marketing
studies performed in the US and Canada, which have
been previously summarized for use in health economic
analysis [13]. The impact of vaccination on IPD was
calculated using serotype-specific vaccine efficacies,
adjusted to the age-specific local serotype distribution
of S. pneumoniae in Turkey [25]. The efficacy of
PHiD-CV, PCV-7 and PCV-13 against IPD was
assumed to be equal for serotypes shared between the
vaccines, and was based on serotype-specific data from
a case–control trial of PCV-7 [26]. Vaccine efficacy
against IPD for each of the additional serotypes con-
tained in PCV-13 and PHiD-CV was estimated as
94.7%, based on the average reported efficacy of the
PCV-7 serotypes [26]. While serotypes 6A and 19A
are not covered by PHiD-CV and PCV-7, they are in
the same serogroups as 6B and 19F, respectively, which
are covered in the vaccines. For PHiD-CV and PCV-7,
vaccine effectiveness against IPD caused by serotype
6A was assumed to be 76%, as described in a previous
study of PCV-7 in the US [26]. No efficacy against
serotype 19A was assumed. Lastly, for PHiD-CV, the
impact of vaccination on invasive NTHi disease was
also considered. This was achieved by estimating the
incidence of invasive NTHi disease. In the absence of
Turkish data, it was assumed to be 5% of the inci-
dence of invasive disease, based on data from the
Netherlands Reference Laboratory for Bacterial Menin-
gitis [27] and applying the efficacy of the PHiD-CV
precursor vaccine against H. influenza including NTHi
as reported in the POET trial (35.6%) [7].
In the absence of serotype-specific data for pneumonia,
the efficacy against ambulatory pneumonia of all three
modeled vaccines was assumed to be equal to that
observed for PCV-7 in the Northern California Kaiser
Permanente study (i.e. 4.3%) [28]. Vaccine efficacy against
all-cause (excluding NTHi) pneumonia hospitalizations
Figure 2 Modeling age-compartments and vaccine efficacy periods. Vaccine efficacy was modeled in three phases: initial ramp-up efficacy
(2–13 months), full efficacy (13 months-3 years) and waning efficacy (3–10 years).
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10- and 13-valent vaccines, respectively, as described in
a previous health economic analysis of PCVs in the
Netherlands [29]. For PHiD-CV, an additional efficacy
against hospitalized all-cause pneumonia (1.068%) was
also included to account for the vaccine’s potential effi-
cacy against NTHi. This additional efficacy is based on
the reported efficacy of the PHiD-CV precursor vaccine
against AOM caused by NTHi (35.3%) [7] and an esti-
mation of the incidence of pneumonia hospitalizations
due to NTHi (3%) as taken from a review of the litera-
ture (i.e. 35.3% × 3% = 1.059%) [30-34].
While NTHi is a recognized cause of pneumonia, the
extent of its role remains unclear, since the typing of
H. influenzae strains is not routine. Within the model,
the incidence of NTHi pneumonia was estimated as 3%.
The rationale for using a conservative estimation of
NTHi pneumonia incidence was informed by the consid-
erable variation amongst estimates reported in the litera-
ture [30-34].
Vaccine efficacy against AOM is based on published
evidence related to randomized control trials with a 3+1
schedule [7,28,35]. Efficacy is modeled for vaccine type
serotypes, non-vaccine type serotypes and H. influenzae
(including NTHi).
Vaccine efficacy data for PCV-7 are from the per
protocol analysis in Eskola et al. [35]. For PHiD-CV,
vaccine efficacy data are based on a study of an 11-
valent version of PHiD-CV, which was found to reduce
AOM episodes caused by S. pneumoniae vaccine sero-
types by 57.6%, and to reduce episodes caused by NTHi
by 35.3% [7]. For PCV-13, the vaccine efficacy against
AOM caused by vaccine-type S. pneumoniae serotypes
was assumed to be equivalent to that of PHiD-CV
(57.6%) because the difference in vaccine efficacy (57.2%
reported by Eskola et al. [35] for PCV-7) was marginal.
We assumed that PCV-7, PHiD-CV and PCV-13 would
induce the same level of serotype replacement in non-vaccine serotypes as that observed for PCV-7 (33%
increase in non-vaccine serotypes) [35].
Probabilistic sensitivity analyses were performed to
assess the effect of uncertainty around the model results.
Point estimates used in the base case as input data were
replaced by distributions (log normal distribution for
vaccine efficacy, beta distribution for disease incidence
rates and disutility values and triangular distribution for
costs). A total of 1,000 simulations were run, each select-
ing an input within the distribution. This allows estima-
tion of the range of possible model outcomes.
Univariate sensitivity analyses were performed in order
to examine the impact of independently varying the
model’s parameters on the costs and quality-adjusted life
years (QALYs) gained for PHiD-CV versus PCV-13.
Results
Projected health outcomes
The model projects that implementation of a 3+1 vac-
cination schedule of PHiD-CV or PCV-13 would lead to
an estimated reduction in incidence, sequelae and deaths
across all diseases compared to PCV-7 in Turkey
(Table 4). When the new vaccines are compared directly,
PCV-13 was projected to prevent 34 more cases of IPD
and 38 more cases of pneumonia hospitalizations than
PHiD-CV. However, PHiD-CV was predicted to have a
significantly greater impact than PCV-13 on all AOM-
related outcomes, including 5,722 hospitalized myringot-
omy procedures and 192,193 general practitioner (GP)
visits. Nevertheless, these results did not translate into a
single death difference between PHiD-CV and PCV-13,
although a sizeable difference between the number of
QALYs saved was apparent, with 933QALYs in favor of
PHiD-CV and 65life years (LYs) in favor of PCV-13.
Projected direct healthcare costs
The projected costs of vaccines and vaccine administra-
tion, as well as medical treatment for pneumococcal
Table 4 Projected health outcomes by vaccination strategy for children <10 years old
Health Outcome* PCV-7 vaccination PHiD-CV vs PCV-7 PCV-13 vs PCV-7 PHiD-CV vs PCV-13
IPD cases 1,991 −190 −225 34
Pneumonia hospitalizations 7,686 −323 −361 38
AOM hospitalizations 24,894 −8,956 −2,234 −5,722
AOM GP visits 2,930,976 −267,212 −75,019 −192,193
Total LYs 1,065,775,026 −2,081 −2,146 65
Total QALYs 906,683,318 −3,156 −2,223 −933
*Negative numbers represents cases/QALYs/LYs in favor of first comparator.
AOM acute otitis media, GP general practitioner, IPD invasive pneumococcal disease, LY life year, PCV-7 7-valent pneumococcal conjugate vaccine, PCV-13
13-valent pneumococcal conjugate vaccine, PHiD-CV pneumococcal non-typeable Haemophilus influenzae Protein D conjugate vaccine, QALY quality-adjusted
life year.
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AOM for children aged <10 years are presented in
Table 5. The total direct cost of medical treatment,
including vaccination costs, under the PCV-7 strategy
is projected to be US$260,444,808. Under price parity
conditions, PHiD-CV and PCV-13 were projected to
reduce this expenditure by US$11.7 million and US
$3.4 million, respectively.
Of the three vaccines considered, PHiD-CV was pre-
dicted to offer the greatest reduction in direct medical
costs, saving US$8.2 million compared to PCV-13.
While PHiD-CV was predicted to save US$37,139 less
than PCV-13 in direct medical costs for IPD and pneu-
monia, this was offset by far greater savings in AOM
costs. Moreover, according to model projections, the
greatest cost burden of pneumococcal disease was treat-
ment of AOM, which accounts for 95% of direct medical
costs allocated for the treatment of vaccine-preventable
S. pneumoniae diseases or US$98.8 million under the
PCV-7 strategy. AOM cost savings of the PHiD-CV
regimen were predicted to be most influential, introdu-
cing an additional saving of US$11.5 million compared
to PCV-7 and US$8.2 million compared to PCV-13.
Incremental cost-effectiveness analyses
Incremental cost-effectiveness analyses were used to
compare a PCV-7 vaccination program with those ofTable 5 Projected direct costs by vaccination strategy for chil
Costs with PCV-7
vaccination, US$ P
Vaccine and vaccine administration cost 156,455,040 0
IPD cost 1,217,684 −
Pneumonia hospitalizations cost 3,939,050 −
AOM cost 98,833,034 −
Total direct costs 260,444,808 −
*Negative numbers represent savings in favor of first comparator.
AOM acute otitis media, IPD invasive pneumococcal disease, PCV-7 7-valent pneumo
PHiD-CV pneumococcal non-typeable Haemophilus influenzae Protein D conjugate vPHiD-CV and PCV-13. These analyses suggest that a
3+1 schedule of PHiD-CV would dominate equivalent
schedules of both PCV-7 and PCV-13. PHiD-CV is
expected to dominate over PCV-7 and PCV-13 because
of higher potential cost savings and greater QALYs gained.
Sensitivity analysis
The replicates obtained from the probabilistic sensitivity
analysis are presented in Figure 3. This analysis indi-
cates that 58.3% of simulations are located in the
south-east quadrant, where PHiD-CV dominates PCV-
13 in terms of QALYs gained and cost savings, while
2.1% of simulations are located in the north-west quad-
rant, where PCV-13 dominates PHiD-CV. Implementa-
tion of a PHiD-CV strategy results in less costs and
provides less QALYs gained compared to PCV-13 in
38.2% of simulations, which are located in the south-west
quadrant, and is expected to generate higher more costs
and provide greater QALYs gained in only 1.4% of simu-
lations (i.e. north-east quadrant) (Figure 3).
While the majority of the model’s variables were found
to have very little influence over the conclusion of dom-
inance in Turkey (i.e. that PHiD-CV was less costly and
more effective than PCV-13), parameters relating to
PHiD-CV efficacy against vaccine serotypes and AOM-
related outcomes were found to be the most sensitive in
the analysis (Figure 4).dren <10 years old
Cost savings, US$*






coccal conjugate vaccine, PCV-13 13-valent pneumococcal conjugate vaccine,
accine.
Figure 3 Probabilistic sensitivity analysis. Monte Carlo simulation of 1,000 simulations.
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Vaccination, which is the second most effective way
(after clean water) to save lives and promote good health
[36], saves around 3 million lives each year worldwide
[37]; reduces suffering; has vastly reduced the incidenceFigure 4 One-way sensitivity analysis. AOM = acute otitis media, CAP =
general practitioner, I/P = inpatient, LL = lower limit, NTHi = non-typeable
vaccine, PCV-13 = 13-valent pneumococcal conjugate vaccine, PHiD-CV = p
conjugate vaccine, Sp = Streptococcus pneumoniae, UL = upper limit.of various diseases; and results in substantial cost savings.
In an analysis by the Centers for Disease Control and
Prevention in the US, every US$1 spent on immunization
saves US$6 in direct medical costs and US$12 in indirect
costs [38]. It has also been estimated that each birthcommunity-acquired pneumonia, CI = confidence interval, GP =
Haemophilus influenzae, PCV-7 = 7-valent pneumococcal conjugate
neumococcal non-typeable Haemophilus influenzae Protein D
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$10 billion in direct medical costs and $33 billion in
indirect costs [39].
The benefit of introducing a widespread vaccination
program can only be judged on the basis of an accurate
estimation of country-specific disease burden. The study
reported here adapted a previously described model for
the UK [13], but used data from 12 Istanbul hospitals
[16] and Turkish Ministry of Health statistics [17] on
burden of disease, resource use and costs. These were
combined with vaccine efficacy estimates, adjusted to
the specific pneumococcal serotype distribution in
Turkey [25].
The projections reported herein suggest that introdu-
cing either PCV-13 or PHiD-CV would greatly reduce
pneumococcal infection disease burden compared with
PCV-7. Not surprisingly, both the PCV-13 and PHiD-CV
vaccines were also predicted to have a greater beneficial
impact on cost savings due to pneumococcal disease and
AOM. These observations are consistent with those
made by other authors [13,40,41].
The modeled projections indicate that PCV-13 is
expected to offer a greater impact on IPD and pneumonia
(by virtue of its greater complement of S. pneumoniae
serotypes) than PHiD-CV. This translates into a saving
of one additional death every year after the launch of a
vaccination program (65 LYs gained over a 1-year period
at a vaccine steady state). However, in terms of cost and
QALYs, this relative reduction in IPD and pneumonia
was grossly outweighed by the substantial reduction in
AOM cases estimated with PHiD-CV. Moreover, when
comparing the cost profiles of the two vaccines, the add-
itional costs saved by PCV-13 in IPD and pneumonia
(around US$37,139) were approximately 200-fold less
than the additional savings in AOM estimated with
PHiD-CV (around US$8.2 million). The relatively greater
impact of PHiD-CV on AOM also contributed to the
prediction that the vaccine would save 933 more QALYs
than PCV-13 over the 1-year period. It was these sub-
stantial differences in direct cost savings and quality of
life that led to PHiD-CV being identified as the most
cost-effective vaccine under the modeled conditions.
The observation that AOM treatment costs drive the
cost-effectiveness of PCVs in children <10 years of age is
as expected, given the substantial prevalence of the dis-
ease within this age group. Previous estimates suggest
that >80% of children will experience ≥1 episode of
AOM by the age of 3 years [42]. AOM is a major burden
for healthcare systems, resulting in around 1.7 times as
many hospitalizations as pneumonia in children aged
0–9 years in the UK; and 73 times as many GP consulta-
tions [43]. Further reducing the incidence of AOM com-
pared with PCV-7 was estimated in this study to
decrease the number of AOM hospitalizations by 7,956and 2,234 for PHiD-CV and PCV-13, respectively, and
the number of GP visits by 267,212 and 75,019, respect-
ively. AOM burden of disease is reflected by the sizeable
annual cost of AOM treatment predicted under all three
of the vaccination schedules considered in the model,
ranging from US$87 million to US$99 million. One
limitation of this study is that AOM incidence was not
available in Turkey, therefore data from other coun-
tries were used to estimate the prevalence of AOM in
Turkey [8,18,19]. A separate scenario was analyzed to
test the base case incidence estimate of 33,000 per
100,000 person years obtained from Garcés-Sánchez
et al. study [18]. The base case incidence rate of AOM
was reduced by - 50% in 0–5 and 5–9 age group
down to 16,500 and 10,095 per 100,000 person re-
spectively. In this scenario PHiD-CV was projected to
dominate PCV-13 as it generates 491 more QALY and
US$5.5 million cost savings.
Historically, researchers have been intrigued by the
differences in efficacy of pneumococcal vaccines against
clinical AOM between the POET [7] and FinOM [35]
trials. However, a direct comparison between the 34%
overall impact against AOM in the POET trial (11-valent
pneumococcal polysaccharide conjugate vaccine conju-
gated to H. influenzae-derived protein D [11-Pn-PD])
versus 7% in FinOM (PCV-7) cannot be made due to
the different settings and designs of these trials. Palmu
et al. [44], former investigators of FinOM, assessed the
impact of variations in case definition, design and local
epidemiology between trials, and concluded that these
factors only account for part of the difference. An exten-
sion of this re-analysis with the POET data set, using a
standardized case definition, confirmed that the original
difference in case definition was not the cause of the
observed AOM efficacy difference. De Wals et al. [45]
assessed various scenarios, adjusting for different factors.
Replacement due to non-vaccine serotypes, not observed
in POET, was identified as a main factor to explain the
divergence. The observed reduction in AOM episodes
due to NTHi in POET with the 11-Pn-PD vaccine was
identified as a secondary factor to explain the diver-
gence. Tangible differences in calculated maximal efficacy
against AOM are thus consistent with those presented in
independent evaluations [46].
The vast amount of antibiotics prescribed for child-
hood AOM has the potential to increase antibiotic resist-
ance [47], which may increase treatment costs and
decrease quality of life. The prevention of AOM by vac-
cination therefore has an important role in the reduction
of antibiotic prescriptions [42]. However, while reducing
the number of AOM cases is likely to reduce the rate of
antibiotic prescription, modeling the impact of vaccin-
ation in this context is complex and was beyond the
scope of the analysis reported here.
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upon the approximations and assumptions used to con-
figure them. Where possible, we endeavored to use
region-specific surveillance data and information from
controlled clinical trials. However, assumptions were
required for certain parameters in the model. In the
absence of any specific efficacy data, the efficacy of the
additional serotypes in PHiD-CV and PCV-13 had to
be estimated using the average efficacy of the serotypes
in PCV-7, but their true efficacy may lie at either ex-
treme of the efficacy range (87% for 19F to 99.9% for
9V). However, this assumption is in line with WHO
guidelines and does not appear to overtly bias the
model [13,48].
A second approximation in the model is the absence
of indirect vaccine effects (e.g. herd protection and sero-
type replacement), which is an important limitation.
PCV-7 has been shown to reduce nasopharyngeal car-
riage of vaccine-type S. pneumoniae serotypes in vacci-
nated and unvaccinated individuals [49-51]. PCVs are
therefore capable of having an additional impact on the
overall transmission of S. pneumoniae within the popu-
lation, which would potentially translate into protec-
tion for the unvaccinated population [52-54]. Lessons
from the large-scale PCV-7 vaccination program in the
US indicate that vaccination can result in substantial
indirect herd effects, e.g. IPD has been reported to have
decreased by 15% in unvaccinated children aged <5 years
[14], and by 29% in unvaccinated children >5 years and
adults [55]. Most deaths from pneumococcal disease
occur in elderly adults [56], as they are more likely to
have compromised immune systems. Excluding a herd
effect on the elderly is therefore likely to have resulted in
an underestimation of the true health gains that a PHiD-
CV, PCV-7 or PCV-13 vaccination program could
achieve. Indeed, indirect effects that increase the number
of IPD cases averted may have a crucial impact on eco-
nomic savings per QALY gained [19,57,58]. Opposing
this effect is serotype replacement, which results in
increased disease from non-vaccine serotypes [59]. At
present in the US, beneficial herd effects appear to out-
weigh negative serotype replacement [14,59]. Indirect
effects of the vaccines (herd effect and serotypes replace-
ment) were not included. Since PCV-7, PHiD-CV and
PCV-13 are directly compared and the potential differ-
ences in indirect effect induced by each vaccine are not
known, the inclusion or exclusion of equal (not differen-
tial) indirect effect for all vaccines won’t impact the
results, because the incremental differences between
three vaccines would be the same with inclusion or with-
out inclusion of indirect effect. On the other hand herd
protection plays an important role in impact on cost-
effectiveness ratio when the vaccines are compared to a
no vaccination strategy.Another weakness of the current analysis is that long-
term complications after meningitis (neurological seque-
lae and severe hearing loss) were not included, due to the
absence of Turkey-specific incidence and cost data.
However, if available incidence data are used (neuro-
logical sequela 7% [60]; hearing loss 13% [61]), this would
result in six fewer cases of long-term complications for
PHiD-CV vs PCV-7 and eight fewer for PCV-13 vs
PCV-7. This small number of cases is not expected to
influence the outcome or conclusions of this study.
Additional assumption is related to the extrapolated
incidence rates of IPD, CAP and AOM in 5–9 age
group. This assumption may have a minor impact on
the results and conclusions, since in 0–10 age group
approximately 90% of IPD, CAP and AOM cases are
occurring in children below 5 years of age.
Another important approximation is related to the
modeling of the impact of the vaccines based on the IPD
serotypes distribution before PCV-7 implementation.
The pre PCV-7 IPD serotypes distribution was used in a
base case in order to have a consistent data set of both
incidence rates and serotypes distribution from the same
time period of pre PCV-7 introduction before 2008. The
impact of PCV-7 is projected using the model. An alter-
native scenario was analyzed using the latest serotypes
distribution from Ceyhan et al. and estimating the im-
pact of vaccination on costs and QALYs gained [62]. In
the scenario analysis PHiD-CV was projected to yield
759 more QALYs and cost savings of US$11.6 million
when compared with PCV-13. The analysis described
here assumes a 3+1 dosing schedule in order to gain
maximum impact from the vaccination program. Al-
though some countries have adopted 2+1 schedules of
PCVs [63], the 3+1 schedule is used in Turkey. Our deci-
sion to focus on 3+1 schedules of PCVs was also based
on a previous cost simulation using UK statistics, which
showed that implementing a 3+1 schedule had incre-
mental health benefits over the 2+1 schedule for PCV-7
currently in place in the UK [45]. This four-dose pro-
gram is in line with the original recommendations for
vaccination with PCV-7 and is supported by data dem-
onstrating that efficacy increases with increasing num-
bers of doses [26].
With over 70 million people, Turkey has the 17th
largest population in the world and the 3rd largest in
Europe [64]. Turkey’s huge population is diverse and
heterogeneous, with discrepancies in income, poverty,
infrastructure, and services between those living in the
east and the west, and between those in urban and rural
areas [65]. This analysis has shown that the use of PHiD-
CV and PCV-13 are more cost-effective than PCV-7 (in
terms of more QALYs gained and costs saved) in this
upper middle income country. These results are in line
with other cost-effectiveness studies of PCVs of various
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[66]) income countries, suggesting that these results may
be applicable to the other, economically heterogeneous,
countries in the Middle East and North Africa (MENA)
region, assuming similar disease incidence rates and
treatment costs.Conclusions
The health economic analysis described here estimates
the relative cost-effectiveness of PHiD-CV, PCV-13 and
PCV-7 vaccination programs in Turkey, using currently
available vaccine efficacy data and region-specific infor-
mation on the burden of pneumococcal disease. Projec-
tions of direct medical costs show that a vaccination
program with any of these vaccines would have a signifi-
cant impact on the economic burden of invasive and
non-invasive pneumococcal disease amongst children
aged <10 years. Over a 1-year period at vaccine steady
state, PHiD-CV and PCV-13, according to model out-
puts, have approximately equivalent impact on mortality
associated with IPD and pneumonia, while PHiD-CV is
projected to prevent approximately three times as many
GP visits for AOM compared to PCV-13. Overall, PHiD-
CV is projected to dominate PCV-13, given its potential
to generate more QALYs and greater estimated health-
care cost savings.
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